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Abstract Selective estrogen receptor modulators (SERMs)
or estrogen agonists/antagonists have shown promise in
osteoporosis in that they have the potential to reduce the
risk of fracture, and also reduce the risk of breast cancer.
SERMs maybe classified according to their core structure,
which is typically a variation of the 17 beta-estradiol
template and subclassified according to the side chain at the
helix 12 affector region. The best known are the triphenyl-
ethylenes such as tamoxifen, used in the management of
breast cancer. However, the clinical application of this class
of SERMs has been limited due to endometrial stimulation.
A second class is the benzothiophenes such as raloxifene
and arzoxifene, which have skeletal benefit with little, if
any, uterine stimulation. Indole-based SERMs such as
bazedoxifene have a 2-phenyl ring system that serves as a
core binding unit. Other classes include benzopyrans and
naphthalenes (eg, lasofoxifene). In this review article, I will
discuss raloxifene and three new SERMs—arzoxifene,
bazedoxifene, and lasofoxifene—that have been recently
studied. I will discuss their effect on bone, breast, and the




GENERATIONS Global Investigation to Determine
Efficacy of Arzoxifene on At-risk
Postmenopasal Patients
MORE Multiple Outcomes of Raloxifene
Evaluation
PEARL Postmenopausal Evaluation and
Risk-Reduction with Lasofoxifene
Introduction
We now have a diverse menu of osteoporosis therapies
including both antiresorptive and anabolic therapies.
Antiresorptive therapies include bisphosphonates, calci-
tonin, and selective estrogen receptor modulators
(SERMs), also called estrogen agonists/antagonists. The
f i r s tS E R M ,r a l o x i f e n e ,w a ss h o w nt or e d u c er i s ko f
vertebral fracture but not nonvertebral fracture with an
important extraskeletal effect of reducing invasive breast
cancer [1]. The potential to reduce fracture risk and breast
cancer risk has led to further development of new SERMs
with the hope that a SERM would also reduce non-
vertebral fracture risk. In this article, I will discuss newer




The MORE trial was an international, randomized,
placebo-controlled 3-year trial of the safety and efficacy
of raloxifene in 7,705 postmenopausal women who met
the World Health Organization criteria for having
osteoporosis [1]. Women were randomized to 60 or
120 mg of raloxifene or placebo. Raloxifene reduced the
risk of vertebral fracture compared with placebo (hazard
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DOI 10.1007/s11914-010-0025-0ratio [HR], 0.7; 95% CI, 0.5–0.8). Raloxifene did not
reduce the risk of nonvertebral fracture. Raloxifene
reduced markers of bone turnover by 26% to 31% for
osteocalcin and by 32% to 34% for CTX-I. Raloxifene
increased bone mineral density (BMD) by 2.6% to 2.7% at
the lumbar spine and 2.1% to 2.4% at the femoral
neck.
Lasofoxifene
The PEARL trial was an international, randomized,
placebo-controlled 5-year trial of the safety and efficacy
of lasofoxifene [2￿￿] in which 8,556 postmenopausal
women with osteoporosis in the femoral neck or spine
were randomized to a placebo, low-dose (0.25 mg) or
high-dose lasofoxifene (0.5 mg). Lasofoxifene at a dose of
0.5 mg/d compared with placebo was associated with
reduced risk of vertebral fracture (HR, 0.58; 95% CI,
0.47–0.70). Lasofoxifene was associated with reduced risk
of nonvertebral fracture (HR, 0.76; 95% CI, 0.64–0.91).
Lasofoxifene improved BMD over 5 years in the
lumbar spine by 3.1% at a dose of 0.5 mg compared with
the placebo group. Lasofoxifene increased BMD in
the femoral neck by 2.9% and by 2.7% in the total
hip.
Bazedoxifene
The bazedoxifene study was a 5-year international, double-
blind, randomized, placebo- and active-controlled trial of
7,492 women at 206 sites [3￿￿]. Results of the first 3 years
have been published and will be discussed here. The results
of the 5 years have been presented but not published.
Treatments included 20 or 40 mg of bazedoxifene, 60 mg of
raloxifene, or placebo taken once daily. Inclusion criteria
included women 55 to 85 years of age with osteoporosis as
d e f i n e db yaB M Do f−2.5 to −4.0 or at least one
radiographic-confirmed vertebral fracture with a BMD
greater than −4.0. Bazedoxifene reduced the risk of new
vertebral fractures at both doses: 20 mg (HR, 0.58; 95% CI,
0.38–0.89), and 40 mg (HR, 0.63; 95% CI, 0.42–0.96);
compared with raloxifene, 60 mg (HR, 0.58; 95% CI, 0.38–
0.89), compared with placebo. For nonvertebral fracture, no
significant differences in nonvertebral fracture rate were seen
in the general study population. However, in a post hoc
analysis of 1,772 women who were at higher risk for
fracture (eg, a femoral neck T-score<−3.0 and/or had at
least one moderate or severe vertebral fracture or more than
one mild vertebral fracture at baseline), bazedoxifene at
20 mg reduced the nonvertebral risk by 50% versus
placebo (P=0.02). In addition, the risk of nonvertebral
fracture risk was 44% lower than with raloxifene in the same
group (P=0.05).
Arzoxifene
Arzoxifene was studied in the GENERATIONS, a multi-
center, placebo-controlled, double-blind 5-year randomized
trial of 9,354 women with osteoporosis (n=5,252) or low
bone mass (n=4,102) [4]. Arzoxifene reduced the risk of
vertebral fracture up to 3 years in patients with osteoporosis
(HR, 0.59; 95% CI, 0.45–0.77; P<0.01) but not non-
vertebral fracture (HR, 0.92; 95% CI, 0.71–1.19; P=0.071).
Results were similar in participants with low bone mass. At
12 months, in participants with low bone mass, arzoxifene
reduced bone markers such as CTX by 32%, was associated
with a 42.1% reduction in CTX, and 33.5% reduction in
P1NP in 12 months, with 3-year increases in BMD of 2.6%
in the total hip, 2.8% in femoral neck, and 2.9% at lumbar
spine. In the absence of nonvertebral efficacy, arzoxifene
has been withdrawn from further clinical development.
Relationship of SERMs Efficacy to Fracture Risk
One of the questions asked of all agents is the relationship
of fracture risk to efficacy. The assumption has been made
that patients with higher fracture risk would have greater
efficacy with an osteoporosis agent. The effects of the
SERMs have not been consistent. Raloxifene, as reported
by McCloskey et al. [5], which had significantly decreased
risk of all clinical fractures and morphometric fractures in
the MORE trial, had no significant interaction of efficacy
with 10-year fracture risk assessment tool (FRAX) proba-
bility. In the case of morphometric vertebral fractures,
efficacy decreased with increasing age. At the 90th
percentile of age, vertebral fracture risk was reduced by
31% independent of FRAX probabilities. In contrast, at
younger ages, efficacy was higher and increased further still
with decreasing fracture probability. In contrast, the same
investigators found that reductions in fracture risk with
bazedoxifene were greater as the probability of fracture risk
increased [6].
Cardiovascular Effects
Selective estrogen receptor modulators offer the promise of
reducing the burden of coronary artery disease (CAD)
based on the promise of lipids and markers of inflammation
being reduced.
Raloxifene failed to lower the risk of CAD in postmen-
opausal osteoporotic women but doubled the risk of venous
thromboembolism. The risk of CAD was lowered in a
subgroup of patients at high risk. In a large, randomized,
controlled trial with CAD as the primary end point,
raloxifene failed to significantly reduce CAD while
152 Curr Osteoporos Rep (2010) 8:151–153significantly increasing the fatal stroke of venous thrombo-
embolism [7].
In the primary trial, bazedoxifene also increased the
risk of venous thromboembolism [3￿￿]. In the PEARL
trial, lasofoxifene reduced the risk of heart disease
events, as well as the risk of stroke, whereas the risk of
deep vein thrombosis remained in line with other SERMs
[2￿￿].
Reports of the effect of arzoxifene on cardiovascular
events have not been published.
Effects on Breast Cancer
Raloxifene has been noted to reduce the risk of invasive
breast cancer [8]. In the GENERATIONS trial, arzoxifene
reduced the risk of invasive breast cancer by 56% after
4 years of treatment (P=0.002). Lasofoxifene reduced the
risk of estrogen receptor–positive breast cancer, 0.3 versus
1.7 cases per 1,000 person-years (HR, 0.19; 95% CI,
0.07–0.56).
Effects on Uterus
Of the newer SERMs in development, lasofoxifene has
been shown to reduce fractures and decrease the risk of
breast cancer but has been associated with increased
incidence of vaginal bleeding and endometrial thickening
and endometrial polyps [9]. However, lasofoxifene has also
shown beneficial effects in the vaginal epithelium [9].
Bazedoxifene has had no adverse effects on endometrium
or breast [10].
Conclusions
Further investigation into new SERMS is warranted to
more clearly define the bone and gynecologic safety and
potential effects on both breast cancer and cardiovascular
risk. It is clear that SERMS differ in their efficacy and
safety profiles.
Disclosure Dr. Stuart L. Silverman has been a consultant for Warner
Chilcott, Roche Pharmaceuticals, Roche Diagnostics, Novartis, Pfizer,
and Eli Lily and Co. He has received grants from Eli Lily and Co. and
Alliance for Better Bone Health. He has also received honoraria from
Eli Lily and Co., Roche Pharmaceuticals, and Pfizer.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
￿￿ Of major importance
1. Ettinger B, Black DM, Mitlak BH, et al.: Reduction in vertebral
fracture risk in postmenopausal women with osteoporosis with
raloxifene: results from a 3 year randomized clinical trial. Multiple
Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA 1999, 282:637–645.
2. ￿￿ Cummings SR, Ensrud K, Delmas PD, et al.: Lasofoxifene in
postmenopausal women with osteoporosis. N Engl J Med 2010,
362:686–696. This is the treatment trial for lasofoxifene.
3. ￿￿ Silverman SL, Christiansen C, Genant HK, et al.: Efficacy of
bazedoxifene in reducing new vertebral fracture risk in postmen-
opausal women with osteoporosis: results from a 3 year random-
ized, placebo and active controlled clinical trial. J Bone Miner Res
2008, 23:1923–1934. This is the treatment trial for bazedoxifene.
4. Reginster JY, McClung MR, Cox D, et al.: The effects of
arzoxifene on fracture incidence in postmenopausal women with
osteoporosis or with low bone mass [abstract OC 30]. Osteoporos
Int 2010, 21(Suppl 1):S23.
5. McCloskey E, Kanis J, Johansson A: FRAX and the effect of
raloxifene on vertebral and non-vertebral fracture. Osteoporos Int
2010, 21(Suppl 1):S7–S24.
6. Kanis JA, Johansson H, Oden A, et al.: Bazedoxifene reduces
vertebral and clinical fractures in postmenopausal women at high
risk assessed with FRAX. Bone 2009, 44:1049–1054.
7. de Villiers TJ: Clinical issues regarding cardiovascular disease and
selective estrogen receptor modulators in postmenopausal women.
Climacteric 2009, 12(Suppl 1):108–111.
8. Nelson HD, Fu R, Griffin JC, et al.: Systematic review:
comparative effectiveness of medications to reduce risk for
primary breast cancer. Ann Intern Med 2009, 151:703–715.
9. Pinkerton JV, Goldstein SR: Endometrial safety: a key hurdle for
selective estrogen receptor modulators in development. Meno-
pause 2010, 17:642–653.
10. Miller PD, Chines AA, Christiansen C, et al.: Effects of
bazedoxifene on BMD and bone turnover in postmenopausal
women: 2 yr results of a randomized, double blind, placebo
and active controlled study. J Bone Miner Res 2008, 23:525–
535.
Curr Osteoporos Rep (2010) 8:151–153 153